Genenta Science S.p.A.GNTA
Price (close)
$0.67
Market cap
$32.4M
P/E
—
Revenue (FY)
—
Net income
-$6.5M
Dividend yield
—
1-year total return
-78.5%
Net margin
—
Revenue growth
—
Debt / equity
—
What Genenta Science S.p.A. does.
are embarking on a strategic transformation to evolve into a next-generation strategic industrial consolidator focused on acquiring privately
held businesses operating in national-security regulated sectors contemplated by the “Golden Power” legislation; however,
we are currently a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net income | -$5.6M | -$5.5M | -$8.5M | -$11.6M | -$8.9M | -$6.5M |
| Free cash flow | -$6.1M | -$7.0M | -$7.4M | -$11.2M | -$6.2M | -$6.9M |
More on GNTA.
- Genenta Science S.p.A. summary
- Genenta Science S.p.A. financial statements
- Genenta Science S.p.A. key metrics
- Genenta Science S.p.A. health scores and style box
- Genenta Science S.p.A. earnings
- Genenta Science S.p.A. dividends
- Genenta Science S.p.A. valuation
- Genenta Science S.p.A. ownership and insiders
- Genenta Science S.p.A. peers
Figures from Genenta Science S.p.A.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.